IZBA Drug Patent Profile

Which patents cover Izba, and what generic alternatives are available?

Izba is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-nine patent family members in twenty-three countries.

The generic ingredient in IZBA is travoprost. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Izba

A generic version of IZBA was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for IZBA

International Patents:	39
US Patents:	4
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,867
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IZBA
DailyMed Link:	IZBA at DailyMed

Paragraph IV (Patent) Challenges for IZBA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IZBA	Ophthalmic Solution	travoprost	0.003%	204822	1	2015-12-30

US Patents and Regulatory Information for IZBA

IZBA is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No			Y
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No			Y
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No			Y
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No			Y

EU/EMA Drug Approvals for IZBA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for IZBA

See the table below for patents covering IZBA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009117316
European Patent Office	2265251
Russian Federation	2503453	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ОБЛАДАЮЩИЕ ЖЕЛАЕМОЙ БИОДОСТУПНОСТЬЮ (PHARMACEUTICAL COMPOSITIONS POSSESSING DESIRABLE BIOAVAILABILITY)
Japan	5654444
Mexico	2010009570	COMPOSICIONES FARMACEUTICAS QUE TIENEN UNA BIODISPONIBILIDAD DESEABLE. (PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY.)
South Korea	101586357
Argentina	070888

Supplementary Protection Certificates for IZBA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	PA2012017,C1920764	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1920764	12C0045	France		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
1920764	2012/033	Ireland		PRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN
1920764	PA2012017	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1920764	1290027-0	Sweden		PRODUCT NAME: TRAVOPROST
1920764	C01920764/01	Switzerland		PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002

Market Dynamics and Financial Trajectory for IZBA

Last updated: February 19, 2026

What is IZBA?

IZBA (generic or proprietary name unspecified here) is a pharmaceutical agent with recent approval or development status. Its market entry, competitive positioning, and revenue prospects depend on several factors, including regulatory approval, patent status, therapeutic class, and market demand.

Regulatory and Patent Status

Aspect	Details
Regulatory approval	Approved by FDA [1], EMA [2], or other agencies?
Market introduction date	When launched or expected to launch?
Patent status	Patent expiry or exclusivity period?
Orphan designation	Designation status influencing market exclusivity?

Note: Precise details about IZBA’s regulatory status and patent life are essential for projecting its market position.

Therapeutic Indication and Market Size

The size of the addressable market depends on IZBA's indication.

• Estimated global market for the therapeutic class (e.g., oncology, cardiology).
• Disease prevalence and incidence rates.
• Existing treatment options and unmet needs.

Disease Area	Global Market (USD billions)	Key Competitors	Unmet Need?
Example: Oncology	25	Drug A, Drug B	Yes
Example: Rare Oncology	5	Limited competitors, orphan status?	Yes

Competitive Landscape

• Proprietary drugs: Patents and exclusivity duration.
• Generics and biosimilars: Impact after patent expiry.
• Market share estimates based on existing data.
• Pricing strategies: Premium pricing vs. competitive discounts.

Market Entry and Adoption

• Reimbursement policies influencing uptake.
• Physician prescribing behavior tracking.
• Patient access programs or support initiatives.
• Distribution channels efficiency.

Revenue Projections and Financial Trajectory

Short-Term (Year 1–3)

• Launch revenues depend on market penetration.
• Initial sales volume estimates.
• Pricing assumption (e.g., average wholesale price).

Year	Estimated Sales (USD millions)	Market Share	Assumptions
2023	$XX	X%	Launch timeframe, initial uptake
2024	$XX	X%	Adoption increase
2025	$XX	X%	Market expansion

Mid to Long-Term (Year 4–10)

• Revenue growth driven by expanded indications, geographic expansion.
• Patent expiration impacts sales volume and pricing.
• Entry of biosimilars or generics reduces revenue margins.

Year	Estimated Sales (USD millions)	Growth Rate	Key factors
2026	$XX	X%	New markets, additional indications
2030	$XX	X%	Patent expiry, biosimilar entry

Cost Structure and Profitability

• R&D costs related to ongoing development.
• Manufacturing expenses.
• Marketing, sales, and administrative expenses.
• Expected margins based on competitor data.

Market Risks and Opportunities

Risks

• Regulatory delays or refusals.
• Competitive threats from generics or new entrants.
• Pricing and reimbursement challenges.
• Clinical trial failures affecting approval or label expansion.

Opportunities

• Rapid market adoption if addressing an unmet need.
• Strategic partnerships with payers or provider networks.
• Geographic expansion into emerging markets.

Key Takeaways

• Thorough understanding of patent timing and regulatory approval influences revenue outlook.
• The therapeutic area's size and competitive landscape determine market potential.
• Initial revenue depends on market entry strategies, pricing, and market access.
• Long-term profitability hinges on lifecycle management, including indications expansion and patent protection.
• Market risks primarily derive from regulatory hurdles, competitive pressures, and reimbursement policies.

FAQs

1. When is IZBA expected to enter the market?
Pending regulatory clearance, timing could range from the current year to the next two years.

2. What are the key competitors for IZBA?
Competitors vary by indication but generally include established therapeutic agents, generics, and biosimilars.

3. How does patent expiry influence IZBA’s revenue?
Patent expiration typically leads to market entry of generics or biosimilars, reducing revenue margins and total sales.

4. What pricing strategy is likely for IZBA?
Pricing depends on therapeutic benefit, competitive landscape, and reimbursement negotiations; premium pricing is possible if the drug addresses unmet needs.

5. What market expansion opportunities exist for IZBA?
Expansion into emerging markets and additional indications can significantly increase sales over time.

---

References

[1] U.S. Food and Drug Administration (2023). Drug Approvals and Labeling. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs
[2] European Medicines Agency (2023). Regulatory milestones. Retrieved from https://www.ema.europa.eu/en/medicines/registration-evaluation

Note: Due to limited information, the specific details of IZBA’s approval status, patent timeline, and indication are hypothetical. Accurate projections require the latest data from regulatory filings and market research.